✦ LIBER ✦

229 SUCCESSFUL CONVERSION FROM MYCOPHENOLATE MOFETIL TO ENTERIC-COATED MYCOPHENOLATE SODIUM (MYFORTIC®) IN LIVER TRANSPLANT PATIENTS WITH GASTROINTESTINAL SIDE EFFECTS

✍ Scribed by G. Robaeys; D. Cassiman; C. Verslype; D. Monbaliu; R. Aerts; J. Pirenne; F. Nevens

Book ID: 117376155
Publisher: Elsevier Science
Year: 2008
Tongue: English
Weight: 55 KB
Volume: 48
Category: Article
ISSN: 0168-8278
DOI: 10.1016/s0168-8278(08)60231-7

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Successful Conversion From Mycophenolate

Successful Conversion From Mycophenolate Mofetil to Enteric-Coated Mycophenolate Sodium (Myfortic) in Liver Transplant Patients With Gastrointestinal Side Effects

✍ G. Robaeys; D. Cassiman; C. Verslype; D. Monbaliu; R. Aerts; J. Pirenne; F. Neve 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 587 KB

Renal Transplant Patients With Gastroint

Renal Transplant Patients With Gastrointestinal Intolerability to Mycophenolate Mofetil: Conversion to Enteric-Coated Mycophenolate Sodium

✍ N. Calvo; A.I. Sanchez-Fructuoso; J. Conesa; A. Moreno; A. Barrientos 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 42 KB

Switching From Mycophenolate Mofetil to

Switching From Mycophenolate Mofetil to Enteric-Coated Mycophenolate Sodium in Liver Transplant Patients With Gastrointestinal Complications

✍ L. Barrera-Pulido; J.M. Álamo-Martínez; L.M. Marín-Gómez; G. Suárez-Artacho; C. 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 361 KB

Improvement of gastrointestinal symptoms

Improvement of gastrointestinal symptoms after conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in liver transplant patients

✍ Alexander H. Toledo; Laura Hendrix; Valorie Buchholz; Erin Fisher; Kimberly Newt 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 95 KB

Conversion from mycophenolate mofetil to

Conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in liver transplant patients presenting gastrointestinal disorders: A pilot study

✍ Jérôme Dumortier; Marie-Claude Gagnieu; Janine Salandre; Olivier Guillaud; Phili 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 83 KB

Gastrointestinal (GI) disorders are one of the main adverse events in patients treated by mycophenolic acid (MPA). The aim of this prospective study was to evaluate the effect of conversion from mycophenolate mofetil (MMF) to enteric-coated mycophenolate sodium (EC-MPS) in liver transplant patients

Conversion From Mycophenolate Mofetil to

Conversion From Mycophenolate Mofetil to Enteric-coated Mycophenolate Sodium in Renal Transplant Recipients With Gastrointestinal Tract Disorders

✍ P. Darji; R. Vijayaraghavan; C.M. Thiagarajan; R.K. Sharma; B. Subbarao; R. Pish 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 342 KB